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Abstract
Introduction. WNT5A (Wnt family member 5A) belongs to the WNT family of secreted signaling glycoproteins 
that play essential role in developmental, physiological and pathological processes. WNT5A was shown to 
take part in carcinogenesis process playing both oncogenic and suppressor functions in various types of human 
malignancies. This study aimed to assess the expression of the WNT5A gene at the mRNA and protein levels 
in the specimens derived from endometrial cancer (EC) or unchanged control endometrium. The associations 
between the WNT5A expression levels and clinicopathological characteristics and survival of EC patients were 
evaluated.
Materials and methods. Total RNA was isolated in order to assess the relative amounts of WNT5A mRNA by 
quantitative polymerase chain reaction (QPCR) in samples of unchanged endometrial control (n = 8) and tumor 
samples of EC patients (n = 28). Immunohistochemistry (IHC) was used to determine the presence of WNT5A 
protein in the sections of formalin-fixed, paraffin-embedded tissue specimens derived from unchanged endome-
trial controls (n = 6) and EC tumors (n = 19). Significance of differences in WNT5A expression levels between 
the studied groups of EC patients and correlations between the WNT5A and demographic data, pathological 
features, hematological parameters and overall survival of the patients were evaluated by statistical analysis.
Results. The level of WNT5A mRNA was decreased in EC in comparison to unchanged endometrium. WNT5A 
expression was associated with primary tumor invasion status exhibiting reduced level of transcripts in EC that 
involved organs beyond the uterus when compared to the uterus-confined cancers. WNT5A immunoreactivity 
was visualized in the cytoplasm and nuclei of EC cells as well as in the luminal and glandular epithelial cells of 
unchanged endometrium. WNT5A mRNA expression levels correlated negatively with cytoplasmic, and positively 
with nuclear immunoreactivity of the WNT5A protein in the EC cells. In addition, the relationships between 
blood leucocyte count (in particular granulocytes and lymphocytes) of patients with EC and their WNT5A mRNA 
and protein expression levels were established. A positive correlation between the nuclear immunoexpression 
of WNT5A protein in the cancer cells in cell nuclei and mean platelet volume in blood was also found.
Conclusions. The results of the first study of WNT5A expression at the transcript and protein levels indicate 
that it could be considered as a potential marker of molecular changes that take place during EC development. 
(Folia Histochemica et Cytobiologica 2019, Vol. 57, No. 2, 84–93)
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Introduction
Endometrial cancer (EC) is the most common gyne-
cological neoplasm diagnosed in developed countries, 
the fourth most common cancer in women after 
breast, lung, and colorectal cancer. Its incidence is 
increasing [1]. Exposure to endogenous and exoge-
nous estrogens associated with obesity, diabetes, early 
onset of menarche, nulliparity, late onset of meno-
pause, older age (≥ 55 years) and use of tamoxifen, 
are considered as the main risk factors leading to EC 
development [2, 3]. Patients are often diagnosed when 
the disease is still limited to the uterus, what results 
in a good prognosis. Thus, the 5-year overall survival 
(OS) for EC varies from 74% to 91% in non-meta-
static patients [4]. 
Major diagnostic and prognostic problems of EC 
assessment are often associated with histopathological 
evaluation. According to WHO classification, seven 
subtypes of EC can be distinguished [5]. The most 
common subtype of EC is an endometrial endometri-
oid adenocarcinoma (EEAC), classified as type I or 
estrogen-dependent cancer [6]. Endometrial serous 
adenocarcinoma (ESC) and clear cell endometrial 
carcinoma (ccEC), aggressive neoplasia carrying 
a poor prognosis, are estrogen-independent and 
are classified as Type II [6]. Several research teams 
have defined immunohistochemical and/or mutation 
profiles to aid in distinguishing EC subtypes [7–9]. 
However, classification of EC by histomorphological 
criteria has a limited reproducibility and is not accu-
rate or precise enough to effectively triage patients 
into optimal treatment groups. Thus, there is a ne-
cessity to develop better diagnostic and prognostic 
markers that could improve the histopathological 
examination [10] and would provide more biologically 
informative data from endometrial tumors that could 
assist in planning the optimal course of treatment for 
the affected individuals.
The WNT family consists of 19 secreted glyco-
proteins which participate in organogenesis during 
the fetal life as well as in physiological and patho-
logical states postnatally [11]. Intracellular signal 
transduction pathways regulated by WNT proteins 
result in cell proliferation, differentiation, migration, 
adhesion and change of cell polarity [11]. The con-
servatively preserved WNT5A (Wnt family member 
5A) protein is crucial for prenatal development, and 
its absence causes intrauterine fetal death associated 
with developmental defects [12]. Alternative splicing 
results in the formation of WNT5A protein isoforms 
[13] which can fulfill both oncogenic and suppres-
sor functions in the process of carcinogenesis [14]. 
Moreover, WNT5A influences the cancer stem cell 
population and tumor microenvironment. It is an 
important molecule for the regulation of cellular se-
nescence, epithelial-mesenchymal transition (EMT), 
metastasis, tumor cell metabolism and chemotherapy 
resistance of cancer cells in various cancer types [15]. 
The expression of the WNT family members, includ-
ing WNT5A, in EC was evaluated by Bui et al. [16]; 
however, they analyzed only a very small group of 
patients with EC. Therefore, the present study was 
designed and performed to analyze and compare the 
expression of the WNT5A gene in unchanged endo-
metrial control and tumor samples of EC patients at 
both mRNA and protein levels by the use of quan-
titative PCR (QPCR) and immunohistochemistry 
(IHC), respectively. We correlated the obtained data 
with clinicopathological features of the patients as 
well as with the OS to assess whether the evaluation 
of WNT5A gene or protein expression can provide 
a new diagnostic and/or prognostic marker in EC. 
Material and methods
Patients. After receiving institutional review board ap-
proval, patients were recruited at Division of Gynecol-
ogy and Obstetrics and Gynecology Oncology Center at 
The Regional Specialist Hospital in Olsztyn, Faculty of 
Medicine, University of Warmia and Mazury in Olsztyn, 
Poland. All participants provided written informed consent 
for tissue and blood sample donation. The control group 
(n = 8) included women (age: 47 ± 7.63, mean ± SD; 
BMI 18.5–25, n = 4; BMI 25–30, n = 2; BMI > 30, 
n = 2), subjected to diagnostic curettage of the uterus and 
surgery, in which histopathological examination of EC and 
endometrial hyperplasia (hyperplasia simplex and complex, 
without atypia and with atypia) proved to be negative. The EC 
group (n = 28) included women (age: 66.95 ± 10.38, mean 
± SD; BMI 18.5–25, n = 3; BMI 25–30, n = 7; BMI > 30, 
n = 18) with histologically diagnosed EC of the uterus, 
detected by diagnostic curettage of the uterine cavity and 
treated with surgery (hysterectomy, salpingo-oophorectomy, 
cytological peritoneal washing and brushing, and pelvic and 
aortic lymph node dissection). Diagnosis of uterine cancer 
and its status were established by means of clinical, labora-
tory and histopathological evaluation. None of the patients 
received any anticancer therapy before the surgery. Ongoing 
acute illnesses (i.e. infection, non-infectious inflammation, 
cardiovascular events) or disease that had occurred within 
the last 30 days, known active malignancy, long-term estro-
gen therapy, polycystic ovarian syndrome, obesity, diabetes 
mellitus and hypertension as well as drug or alcohol abuse, 
excluded patients from the study. After the surgery, data on 
the OS were collected for all patients.
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Material collection and clinical parameters estimation. 
Blood samples were collected from the fasting patients be-
fore surgery. Blood morphology parameters and activated 
partial thromboplastin time (APTT) were measured using 
Cobas 6000 multianalyzer (Roche Diagnostics Ltd., Basel, 
Switzerland).
Tissue samples (5 × 5 × 5 mm) were taken from areas of 
endometrial tumors without blood-cysts, hemorrhage or ne-
crosis which could disturb further molecular assays. Multiple 
sample blocks were taken from the same tumor-suspected 
area to compensate for eventual tumor heterogeneity. The 
samples were snap-frozen in liquid-nitrogen immediately 
after excision and stored at –80°C for mRNA isolation and 
further molecular studies. Tissue sections for routine diag-
nostic pathomorphological assessment and IHC were fixed 
in a 10% neutral-buffered formalin. After 12 h sections were 
dehydrated in a graded ethanol series (50–96%), cleared 
in xylene and embedded in paraffin for further processing. 
Tumor phenotype classification. The criteria of TNM system 
following American Joint Committee on Cancer (AJCC) 
were adopted to establish primary tumor status [17]. Patients 
classified as T1a (n = 10) and T1b (n = 6), T2 (n = 7) and 
T3 (n = 5) were considered. Subsequently, the patients were 
grouped depending on: the depth of myometrium invasion as 
less or more than halfway (n = 12 and n = 16, respectively), 
uterine cervix infiltration as negative and positive (n = 14 
and n = 14, respectively) and uterus-limited tumor growth 
or involvement of other organs by direct extension beyond 
the uterus (n = 23 and n = 5, respectively). Pathomorpho-
logical assessment was based on a routine light microscopy 
evaluation. Malignancy grade was assessed according to 
the International Federation of Gynecology and Obstetrics 
(FIGO) system [18], as low grade (G1; n = 2), moderate 
grade (G2; n = 19), and high grade (G3; n = 7). Grades 1 
and 2 were grouped together (named further G2). The ab-
sence (n = 15) or presence (n = 13) of endometrial fibroids 
(myomas) were also recorded for each patient.
Total RNA isolation and Real time PCR. Endometrial 
tissues were homogenized using MagNA Lyser Instrument 
and MagNA Lyser Green Beads (Roche Molecular Systems, 
Inc., Pleasanton, CA, USA). Extraction of total RNA was 
conducted using mirVana Isolation Kit (Ambion; Thermo 
Fisher Scientific, Inc., Waltham, MA, USA), according to 
the protocol provided by manufacturers. The quality and 
quantity of isolated RNA was estimated with NanoDrop 
1000 spectrophotometer (Thermo Fisher Scientific, Inc.). 
Obtained RNA samples were stored at –80°C until further 
analysis. The reverse transcription was conducted according 
to the protocol of HighCapacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystem; Thermo Fisher Scientific, Inc., 
Waltham, MA, USA). Quantification of WNT5A and pep-
tidylprolyl isomerase A (PPIA) cDNA in collected samples 
(Hs00998537_m1 and Hs99999904_m1) was carried out 
using ABI 7500 Fast Real-Time PCR System and TaqMan® 
Fast Advanced Master Mix (all: Applied Biosystem; Ther-
mo Fisher Scientific, Inc.) according to the manufacturer’s 
instructions, and using the following conditions: polymer-
ase activation for 20 sec at 95°C, followed by 40 cycles of 
denaturation at 95°C for 3 sec and annealing/extension at 
60°C for 30 sec. All samples were quantified in duplicate. 
No template control reactions were performed for each 
QPCR run. Standard curves consisting of serial dilutions of 
the appropriate cDNA were used to control the efficiency 
of QPCR. Relative quantification of WNT5A expression 
was evaluated using the ddCt method [19]. Quantified gene 
had the Ct normalized against PPIA expression (dCt) as the 
reference [20]. 
Immunohistochemistry. Formalin-fixed, paraffin-embedded 
blocks of unchanged (control) endometrium obtained from 
6 patients without EC, and fragments of tumor samples 
from 19 patients with EC, were cut into 5 μm-thick sections, 
soaked in xylene and rehydrated in a series of decreasing 
ethanol dilutions (96–50%). Antigen retrieval was carried 
out using Epitope Retrieval Solution (pH 6; Dako; Agilent 
Technologies Inc., Santa Clara, CA, USA), microwaving for 
12 min at 97°C. Endogenous peroxide activity was blocked 
in a solution of 3% hydrogen peroxide in methanol for 
10 min at room temperature (RT). Tissue sections were 
incubated with 2.5% normal horse serum (NHS; Vector 
Laboratories; Maravai Life Sciences, Inc., Chicago, IL, 
USA) in buffer containing 0.1 M PBS and 3% bovine serum 
albumin (BSA; Sigma-Aldrich; Merck, KGaA, Darmstadt, 
Germany) for 30 min at RT. Rabbit anti-human WNT5A 
(H-58) antibody (sc-30224; Santa Cruz Biotechnology Inc., 
Dallas, TX, USA), were diluted in NGS/PBS/BSA buffer 
(1:100). After overnight incubation at 4°C with primary 
antibody, slides were washed 3 times with PBS containing 
Tween20 (Sigma-Aldrich; Merck, kGa) and incubated for 
30 min at RT with goat anti-rabbit antibody diluted accord-
ing to the protocol provided by manufacturers (ImmPRESS 
Universal reagent Anti-Mouse/Rabbit Ig; Vector Laborato-
ries; Maravai Life Sciences, Inc.). Reaction was visualized 
after short incubation with 3,3’-diaminobenzidine (DAB; 
Liquid DAB + Substrate Chromogen System; Dako; Ag-
ilent Technologies Inc.). After counterstaining in Mayer’s 
hematoxylin (Sigma-Aldrich; Merck, KGaA), dehydration 
in series of alcohol dilutions (50–96%) and mounting in 
DPX medium (Sigma-Aldrich; Merck, KGaA) slides were 
vied using XC-50 camera mounted on Olympus BX-41 
(Olympus Corporation, Tokyo, Japan) light microscope by 
a pathologist who was blinded to the patients’ clinical data. 
Pictures were taken with Panoramic Digital Slide Scanner 
MIDI (3DHistech Ltd., Budapest, Hungary). Negative 
controls were obtained by incubation of sections without 
primary antibody.
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The estimation of WNT5A staining intensity and hetero-
geneity. The classification of intensity and heterogeneity 
of the staining were conducted according to the IRS (im-
munoreactivity score) scale as described by Remmele and 
Stegner [21]. Briefly, the staining intensity was estimated 
as 1 (the weakest), 2 (moderate), or 3 (the most intense). 
Heterogeneity characterized the proportion of positively 
stained tumor cells was evaluated as 0 points, absence of 
cells with positive reaction; 1 point, 1–10%; 2 points, 1–50%; 
3 points, 51–80%; 4 points, > 80% cells with positive reac-
tion by estimation on screening wide areas within each tissue 
section. The obtained values of intensity and heterogeneity 
were multiplied and scored from 0 to 12 points. All cases 
with negative immunoreactivity were scored as 0.
Statistical analysis. All statistical analyses were conducted 
using GraphPad PRISM v. 6.0 software (GraphPad Soft-
ware, Inc., San Diego, CA, USA). Comparisons of WNT5A 
mRNA and immunoreactivity levels in unchanged and endo-
metrial tumor samples were conducted with Mann-Whitney 
tests. Statistical differences of mRNA levels between EC 
tissue groups in respect to: primary tumor status, tumor 
myometrial invasion, infiltration of the tumor on the cervix, 
invasion beyond the uterus, malignancy grade and presence 
of endometrial fibroids (myomas) were examined using 
Kruskal-Wallis and Mann-Whitney tests. All correlations 
of WNT5A gene and protein expression in both studied pa-
tient groups were calculated using a Spearman test. Survival 
curves were plotted according to the Kaplan-Meier method 
and the significance of differences in OS between groups 
of patients was evaluated by the log-rank test. Differences 
were considered to be statistically significant at p value less 
than 0.05.
Results
Characteristics of the patients
Demographic data and blood parameters of control 
and EC patients included in the study are presented 
in Table 1.
WNT5A expression at the mRNA level in EC 
In both control and EC samples, the presence 
of WNT5A mRNA was observed. Samples with 
WNT5A expression ratio below 1.0 were considered 
as down-regulated and those with ratio above 1.0 us 
up-regulated. The WNT5A transcript level was de-
creased in 24/28 (85.72%) and was elevated in 4/28 
(14.28%) patients with EC. The mean WNT5A gene 
expression was reduced in EC patients compared to 
control group (p < 0.0001; Fig. 1A). 
WNT5A mRNA levels were significantly lower in 
the group of patients characterized by tumor inva-
sion beyond the uterus when compared to the uter-
us-confined EC samples (p < 0.05; Fig. 1E). WNT5A 
expression also tended to correlate with the depth 
of myometrial invasion exhibiting lower transcript 
level in tumors that have grown deeper than halfway 
through the myometrium as compared to those which 
invaded less than the half of myometrium thickness, 
but this difference was not confirmed by the statistics 
(p = 0.06; Fig. 1C). There were no statistically signif-
icant associations between the WNT5A mRNA levels 
and primary tumor status (established as T1a, T1b, T2 
and T3; Fig. 1B), infiltration of the tumor on the cervix 
(absent or present; Fig. 1D), malignancy grade (G2 
and G3; Fig. 1F) and occurrence of uterine fibroids 
(absent or present; Fig. 1G).
The immunoreactivity of the WNT5A protein  
in control and EC tissue
Tissue samples of 6 control and 19 EC patients pre-
viously analyzed for their WNT5A mRNA expression 
levels were subjected to IHC in order to assess the 
immunoexpression of WNT5A protein in the normal 
endometrium and EC cancer cells.
Representative microphotographs of IHC pre-
senting the location of WNT5A protein in the control 
endometrium and tumor tissue of EC patients are 
Table 1. Demographic data and blood parameters of the 
studied cohort of patients
Units Control Endometrial cancer
N 8 28
Age years 047 ± 7.63 66.95 ± 10.38
BMI kg/m 27.88 ± 5.920 31.39 ± 5.470
RBC 106/μl 4.57 ± 0.50 4.77 ± 0.45
Hb g/dl 12.16 ± 1.890 13.86 ± 1.360
Ht % 38.28 ± 4.630 41.88 ± 3.170
WBC 103/μl 7.18 ± 1.60 7.36 ± 2.14
Granulocytes % 63.59 ± 7.100 60.32 ± 8.740
Neutrophils % 61.34 ± 8.080 57.95 ± 9.260
Eosinophils % 01.6 ± 0.73 1.94 ± 1.28
Basophils % 0.52 ±0.260 0.43 ± 0.26
Lymphocytes % 28.46 ± 6.070 30.46 ± 7.830
Monocytes % 5.79 ± 1.06 6.49 ± 1.81
Platelets 103/μl 296.4 ± 78.52 229.9 ± 60.26
MPV fl 10.5 ± 0.96 10.93 ± 0.780
APTT s 26.47 ± 1.750 27.49 ± 3.610
The results are presented as means ± SD. Abbreviations: BMI — Body 
Mass Index; RBC — Red Blood Cells; Hb — Hemoglobin; Ht — He-
matocrit; WBC — White Blood Cells; MPV — Mean Platelet Volume; 
APTT — Activated Partial Thromboplastin Time
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shown in Figure 2. The figures presenting negative 
control samples were not shown.
The histologically-unchanged endometrial frag-
ments showed dominant, strong, homogenous positive 
WNT5A immunoreactivity in the cytoplasm and, 
sporadically, in the nuclei of epithelial cells, whereas 
in tumor tissue, WNT5A protein staining were mainly 
present in the nuclei of cancer cells. When control and 
EC tissue sections were compared, qualitative differ-
ences between the immunoreactivity in cytoplasmic 
and nuclear compartments were observed (Fig. 2). 
However, there were no quantitative alterations of 
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Figure 1. Quantitative Real-time PCR analysis was used to compare WNT5A gene expression in tumor tissue of patients with 
endometrial cancer (EC) and normal endometrial tissue (control). WNT5A mRNA levels in control endometrial samples 
(n = 8) and EC samples (n = 28) (A). Comparison of the WNT5A mRNA level in a control endometrial samples and samples 
of EC patients depending on the primary tumor status (B), tumor myometrial invasion (C), absence (0) or presence (1) of 
tumor infiltration on the cervix (D), presence at the area or beyond the uterus (E), grade (F), absence (0) or presence (1) 
of endometrial fibroids (G). Gene expression data were normalized against PPIA mRNA levels and presented as WNT5A 
gene expression ratios ± SD as described in Methods.
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WNT5A immunoreactivity in cytoplasm and nuclear 
compartments between the unchanged endometrium 
and EC samples (p > 0.05; Fig. 3 A and B, respectively).
WNT5A protein immunoexpression measured 
on the basis of the IRS scale in the cytoplasmic and 
nuclear compartments of EC cells did not correlate 
with clinicopathological characteristics of the patients 
(data not showed).
Correlations between WNT5A mRNA levels  
and WNT5A protein immunoreactivity  
in the cytoplasm and nuclei of tumor cells
A negative correlation was observed between WNT5A 
mRNA expression and protein immunoexpression in 
the cytoplasm of EC cells (Rho = –0.55; p < 0.05). In 
contrast, a positive correlation was observed between 
the WNT5A transcript levels in EC tumor samples and 
Figure 2. Representative examples of WNT5A protein immunoreactivity in normal endometrium (A, B) and endometrial can-
cer (EC) samples depending on the degree of histological differentiation; endometrium at grade 2 (C, D) and grade 3 (E, F) 
of EC progression. The immunohistochemical reactions were performed as described in Methods. 
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Figure 3. Quantitative analysis of the immunoreactivity of WNT5A protein in cytoplasmic (A) and nuclear (B) compartments 
of control endometrium (n = 6) and endometrial cancer (EC) samples (n = 19). The immunoreactivity score (IRS) values 
are shown as mean ± SD.
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WNT5A immunoreactivity in the nuclei of cancer cells 
(Rho = 0.60; p < 0.01). 
Correlations between blood parameters  
and WNT5A mRNA expression levels and protein 
immunoreactivity in EC specimens
In patients with EC, WNT5A gene expression corre-
lated positively with the count of leukocytes (WBCs; 
p < 0.05) and the percentage of granulocytes 
(p < 0.05), and negatively with the percentage of 
lymphocytes in blood (p < 0.5; Table 2). 
In patients with EC, we observed negative correlation 
between the cytoplasmic immunoreactivity of the WNT5A 
protein and percentage of granulocytes (p < 0.01) or 
neutrophils (p < 0.01) in blood when the protein in the 
cytoplasm of EC cells was concerned (Table 2). The 
percentage of lymphocytes in blood positively correlated 
with the immunoreactivity of WNT5A in the cytoplasm 
of EC cells (p < 0.01; Table 2). Mean platelet volume 
(MPV) was the only blood parameter which positively 
correlated with WNT5A protein immunoreactivity in the 
nuclei of EC cells (p < 0.05). No correlations with age, 
BMI as well as or other estimated blood parameters such 
as RBC, WBC and platelets counts, types of leukocytes, 
hemoglobin (Hb), hematocrit (Ht), MPV and APTT, 
were found when nuclear localization of WNT5A was 
considered in EC patients (Table 2).
Correlations between WNT5A gene and protein 
expression and OS of patients with EC
The evaluation of the WNT5A gene expression level as 
a prognostic factor in the studied group of the patients with 
EC was assessed after the follow up of patients (n = 28) 
and the median observation period was 59 months. 
During the observation period 25% (n = 7) patients 
died. We found a significant correlation between the 
tumor grade and OS of the patients (p < 0.001; Fig. 4A). 
In order to investigate associations between OS 
and WNT5A expression EC specimens were divided 
into the respective cohorts. Based on the median 
WNT5A mRNA relative expression (RQ = 0.495) 
the patients were divided into two groups regarded as 
< 0.495 (n = 14) and > 0.495 (n = 14). Consequently, 
the patients were dichotomously divided on the basis 
of their median value for the cytoplasmic (IRS = 4) or 
nuclear (IRS = 6) WNT5A immunoreactivity score. 
We found that the expression level of WNT5A mRNA 
(Fig. 4B) as well as the intensity of cytoplasmic or 
nuclear WNT5A immunoreactivity (Fig. 4C and D, 
respectively) did not correlate with patients’ OS. 
Discussion
There is an urgent need for intense research in the 
field of molecular biology of endometrial tumors in or-
der to detect the molecular markers of carcinogenesis 
process. The present study is the first that used both 
QPCR and IHC techniques to establish WNT5A ex-
pression at the transcript and protein levels in the EC 
tissue. Our study demonstrated that WNT5A mRNA is 
down-regulated in the tumor samples as compared to 
normal endometrial tissue fragments. These findings 
support the study of Bui et al. [16] who investigated 
the expression of seven genes belonging to the WNT 
family in neoplastically-altered and normal endome-
trium by ribonuclease protection assay. Their results 
suggested reduced level of WNT5A expression in EC 
tumor tissue and human EC cell lines [16]. Unfor-
tunately, the study of Bui et al. involved only four 
patients with EC and 11 control cases and its findings 
were neither supported by statistical analysis nor the 
correlations between WNT5A expression and clinico-
pathological parameters [16]. Therefore, our research 
was carried out on a larger cohort of patients and is 
the first study which shows associations between the 
reduced WNT5A expression and increasing invasive 
properties of EC tumors. 
In our cohort of the patients with EC the WNT5A 
gene expression was markedly reduced in the tum-
ors that spread outside the uterus as compared to 
the organ-confined cases. Our results suggest that 
Table 2. Correlations between blood parameters and WNT5A 
mRNA levels and WNT5A protein immunoreactivity in 
cytoplasmic and nuclear compartments of endometrial 
cancer cells
WNT5A
mRNA
WNT5A protein
Cytoplasm Nucleus
Age –0.22 0.18 –0.16
BMI 0.31 –0.39 0.23
RBC –0.01 –0.19 –0.08
Hb –0.15 0.02 –0.19
Ht 0.24 0.05 –0.13
WBC 0.39* –0.36 0.15
Granulocytes 0.42* –0.66** 0.24
Neutrophils 0.32 –0.61** 0.30
Eosinophils –0.03 –0.04 –0.32
Basophils 0.18 0.12 –0.35
Lymphocytes –0.38* 0.67** –0.20
Monocytes –0.09 0.22 0.005
Platelets 0.10 0.006 –0.30
MPV 0.30 –0.07 0.51*
APTT –0.09 –0.18 0.29
Abbreviations as in the legend to Table 1. Asterisks indicate statistical 
significance; *p < 0.5; **p < 0.01).
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Figure 4. Analysis of the overall survival (OS) of patients with endometrial cancer (EC). Kaplan-Meier survival curves of 
EC patients relating to (A) the histological grade of EC tumor (n = 28), (B) levels of WNT5A mRNA (n = 28), (C) cyto-
plasmic (n = 19) and (D) nuclear (n = 19) immunoreactivity of the WNT5A protein. P-values of log-rank test are shown. 
decreased WNT5A mRNA level could also correlate 
with the depth of invasion through myometrium. 
Although these findings could suggest tumor sup-
pressor role of WNT5A in EC, we did not disclose 
any significant relationship between its expression 
levels and overall survival of the patients. Indeed, 
the precise status of the WNT5A gene as a factor that 
might have influenced cancer progression has not 
been established yet and the opposing observations 
in other human tumors imply that role of WNT5A 
protein could be tissue- and/or cancer-specific [14]. 
In the female reproductive system the decreased 
expression of WNT5A was documented in epithelial 
ovarian cancer and this reduction was attributed to 
the hypermethylation of the gene promoter [22]. In 
contrast to the latter study, Peng et al. found that 
WNT5A immunoreactivity was increased in the ovar-
ian cancer cells as compared to benign tumors and 
normal ovarian tissue [23]. Furthermore, elevated 
level of WNT5A protein was associated with shorter 
overall and progression-free survival of the patients 
with ovarian cancer [23]. Also in patients with cervical 
cancer WNT5A expression was found to be either de-
creased [13] or increased [24]. Using QPCR and IHC 
techniques Lin et al. [24] showed that the expression 
of WNT5A mRNA was up-regulated in the primary 
cervical tumors and WNT5A immunoreactivity in 
cancer cells correlated with the occurrence of distant 
metastases and worse prognosis. These discrepancies 
may be partially explained by the findings of Bauer et 
al. [13] who demonstrated that the tumor-promoting 
or tumor-suppressing role of WNT5A in cervical 
cancer can be attributed to the differential expression 
of two WNT5A isoforms that have distinct effects on 
cancer-relevant signaling pathways. 
In our study the immunoreactivity of the WNT5A 
protein was observed not only in the cytoplasm but 
also in the nuclei of EC cells and, to a lesser extent, 
in some epithelial cells of the control endometrial 
tissues. Interestingly, WNT5A transcription can re-
sult in the synthesis of two different isoforms, long 
(380 amino-acids; The Consensus CDS accession 
number: CCDS46850) and short (365 amino-acids; 
CCDS58835) [25] that could be characterized by 
distinct biological activity [13]. The results of in silico 
analysis of their amino-acid sequences using nuclear 
localization signals (NLS) mapper [26] recognized 
a single putative NLS within the N-terminus of long 
WNT5A isoform and lack of it in the short isoform. 
Basing on NLS prediction it could be assumed that 
localization of WNT5A immunoreactivity within the 
cell may differ depending on the type of expressed 
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isoform, with long isoform being directed both to the 
cytoplasm and nucleus and short isoform expressed 
exclusively in the cytoplasm [26]. Therefore, we sug-
gest that the changes in the subcellular localization 
of WNT5A immunoreactivity are associated with 
the altered expression pattern of WNT5A isoforms 
as it was demonstrated in other human cancers such 
as cervical cancer, breast cancer and neuroblastoma 
[13]. The QPCR assay used in our study did not dis-
criminate between the mRNA variants encoding for 
long and short WNT5A isoforms. In our immuno-
histochemical study, we could detect both WNT5A 
protein isoforms, since the applied primary antibody 
recognizes 23–80 aa of the long isoform as well as 
15–72 aa of the short WNT5A isoform, respectively. 
Thus, further studies aiming to determine the ex-
pression of WNT5A isoforms in EC samples could 
clarify whether the possible role of this protein in 
EC pathogenesis is isoform-specific. Furthermore, 
our results showed that WNT5A mRNA correlated 
negatively with cytoplasmic and positively with nucle-
ar WNT5A immunoreactivity levels in EC cells. We 
believe that the latter observation could be, at least 
partially, also elucidated by the analysis of WNT5A 
expression with respect to the expressed variants of 
transcript or isoforms.
Our study revealed that WNT5A mRNA and 
immunoreactivity levels correlated with preoper-
ative counts of white blood cells and MPV. Since 
the correlations with granulocytes and lymphocytes 
count were found for the cytoplasmic but not nuclear 
immunoexpression of WNT5A, its role as secretory 
molecule and modulator of immune processes can be 
considered [15]. Other authors have shown that bio-
markers of inflammation such as elevated neutrophil 
to lymphocyte ratio or platelet to lymphocyte ratio 
are significant prognostic factors in EC and correlate 
with worse prognosis [27]. In our study the lower 
cytoplasmic immunoexpression of WNT5A was pos-
itively associated with lymphocyte and negatively with 
neutrophils counts. This relationships could indicate 
the existence of direct or indirect links between the 
WNT5A expressed in endometrial tumor and inflam-
matory processes. Indeed, WNT5A protein have been 
considered tumor-derived immunomodulator that has 
been shown to influence chemotactic cell migration 
in ovarian cancer cell line SKOV-3 [28] and promote 
differentiation of regulatory T-cells by activation of 
dendritic cells in melanoma [29]. Interestingly, it was 
demonstrated that WNT5A potentiated thromboxane 
A2 mimetic-induced platelet aggregation and there-
fore the secretion of this protein by circulating cancer 
cells might promote metastatic progression suggesting 
that WNT5A can promote tumor progression by its 
interaction with the platelets [30]. It cannot be exclud-
ed that in EC, WNT5A has analogous functions to 
those reported in the aforementioned studies [28–30]. 
However, further experiments are needed to evaluate 
its importance in establishing of tumor microenviron-
ment and blood-borne metastasis. 
In conclusion, the investigations of the WNT5A 
expression in the endometrial cancer suggest that this 
signaling molecule could function in the development 
of this malignancy as tumor suppressor and/or modu-
lator of immune response and could be considered as 
a potential marker in EC. However, the precise role 
of WNT5A in the pathogenesis of endometrial cancer 
must be elucidated in further experiments.
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